Advertisement
"We are excited that Roche shares our enthusiasm for MEM 3454 and itspotential to address the cognitive deficits associated with debilitating CNSdisorders," stated Vaughn M. Kailian, President and Chief Executive Officer ofMemory Pharmaceuticals. "We have aggressively advanced MEM 3454 throughearly-stage clinical trials, including a positive Phase 2a trial inAlzheimer's disease. We believe that Roche's continued commitment to theprogram, together with its expertise in later-stage clinical development andcommercialization, will provide the support and capabilities to realize thefull potential of this compound."
Advertisement
In a recently completed Phase 2a study in Alzheimer's disease patients,MEM 3454 demonstrated a statistically significant effect on multiple measuresof cognition. The compound is currently being evaluated in a Phase 2a trialin CIAS, with top-line results expected in the fourth quarter of 2008. Thetrial is expected to enroll approximately 160 patients and is designed toassess the safety, tolerability and cognitive effects of three doses of MEM3454 in patients with CIAS. In addition, Memory Pharmaceuticals and Rocherecently expanded their schizophrenia development program for MEM 3454 toinclude a biomarker study, which will be funded by Roche. MemoryPharmaceuticals expects to initiate the biomarker trial this summer, withresults expected by early 2009.
MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highlyspecialized receptor found in the central nervous system. Compounds acting onthis receptor could be beneficial in the treatment of Alzheimer's disease andschizophrenia, as well as other psychiatric and neurological disorders.
Conference Call Information
Memory Pharmaceuticals will hold a conference call today, May 2, 2008 at9:00 a.m. EDT to discuss this announcement. The conference call will also bebroadcast live from the "Investors" section of the Company's website. MemoryPharmaceuticals' senior management will host the conference call. Investorsand other interested parties may access the call as follows:
An audio replay of the conference call will be available from 11:00 a.m.EDT on Friday, May 2, 2008, until Friday, May 9, 2008. To access the replay,please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enterpasscode number 95627100. An audio replay of the conference call will also beavailable under the "Investors" section of the Company's website during thesame period.
About Memory Pharmaceuticals
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused ondeveloping innovative drugs for the treatment of debilitating CNS disorders,many of which exhibit significant impairment of memory and other cognitivefunctions, including Alzheimer's disease and schizophrenia. For additionalinformation, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that are subject torisks and uncertainties. All statemen
